This is a working overview of reversed-phase HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-25 and is reviewed periodically as new material appears.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Includes the 39-residue backbone and the attached fatty diacid |
| Molecular weight | Approximately 4813 Da | Average mass; the monoisotopic value is slightly lower |
| Receptor targets | GIP receptor and GLP-1 receptor | Dual engagement defines the pharmacological class |
| Backbone length | 39 amino acids | Sequence modified from native glucose-dependent insulinotropic polypeptide |
| Albumin interaction | Reversible, mediated by the fatty diacid | Slows renal clearance and lengthens circulation time |
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.
The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.
Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.
== University == Govt. Medical College Patiala is affiliated to Baba Farid University of Health Sciences Faridkot, Established in the memory of great Sufi Saint Baba Farid by Punjab government in July, 1900 by an Act of the State Legislature, which was established in 1999.
=== Biological applications === Initially developed for geochemical and related research, NanoSIMS is now utilized by a wide variety of fields, including biology and microbiology. In biomedical research, NanoSIMS is also referred to as multi-isotope imaging mass spectrometry (MIMS). The 50 nm resolution allows unprecedented resolution of cellular and sub-cellular features (as reference, the model organism E. coli is typically 1,000 to 2,000 nm in diameter). The high resolution that it offers allows intracellular measurement of accumulations and fluxes of molecules containing various stable isotopes. NanoSIMS can be used for pure cultures, co-cultures, and mixed community samples. The first use of NanoSIMS in biology was by Peteranderl and Lechene in 2004, who used a prototype of NanoSIMS to examine and measure carbon and nitrogen isotopes of eukaryotic cells. This study was the first time that carbon and nitrogen isotope ratios were directly measured at a sub-cellular scale in a biological sample.
== External links and resources == "Cold Chain Management", 2003, 2006, [1] Brody, A. L., and Marsh, K, S., "Encyclopedia of Packaging Technology", John Wiley & Sons, 1997, ISBN 0-471-06397-5 Lockhart, H., and Paine, F.A., "Packaging of Pharmaceuticals and Healthcare Products", 2006, Blackie, ISBN 0-7514-0167-6
Baker's yeast – used as a leavening agent in baked foods such as breads, cakes, and pies. Bouillon cubes – are dehydrated bouillon (French for broth) or stock formed into small cubes about 15 mm per side. They are typically made by dehydrating vegetables, meat stock, a small portion of fat, salt, and seasonings, and shaping the resulting solids into small cubes. Vegetarian and vegan types are also made. Instant breakfast – typically refers to breakfast food products manufactured in a powdered form, which are generally prepared with the addition of milk and then consumed as a beverage. An example is Carnation Instant Breakfast, introduced in 1964.
=== COVID-19 === The COVID-19 pandemic in 2020 produced a drastic tightening of border controls across the globe. Many countries and regions have imposed quarantines, entry bans, or other restrictions on citizens of, or recent travellers to, the most affected areas. Other countries and regions have imposed global restrictions that apply to all foreign countries and territories, or prevent their own citizens from travelling overseas. The imposition of border controls has curtailed the spread of the virus, but because they were first implemented after community spread was established in multiple countries in different regions of the world, they produced only a modest reduction in the total number of people infected These strict border controls economic harm to the tourism industry through lost income and social harm to people who were unable to travel for family matters or other reasons. When the travel bans are lifted, many people are expected to resume travelling. However, some travel, especially business travel, may decrease in the long term as lower-cost alternatives, such as teleconferencing and virtual events, are preferred. A possible long-term impact has been a decline of business travel and international conferencing, and the rise of their virtual, online equivalents. Concerns have been raised over the effectiveness of travel restrictions to contain the spread of COVID-19.
Sources: en.wikipedia.org
Certain bacteria have a polysaccharide outer coat that is poorly immunogenic. By linking these outer coats to proteins (e.g., toxins), the immune system can be led to recognize the polysaccharide as if it were a protein antigen. This approach is used in the Haemophilus influenzae type B vaccine.
acetan (Acetobacter xylinum) alginate (Azotobacter vinelandii, Pseudomonas spp.) cellulose (Acetobacter xylinum) chitosan (Mucorales spp.) curdlan (Alcaligenes faecalis var. myxogenes) cyclosophorans (Agrobacterium spp., Rhizobium spp. and Xanthomonas spp.) dextran (Leuconostoc mesenteroides, Leuconostoc dextranicum and Lactobacillus hilgardii) emulsan (Acinetobacter calcoaceticus) galactoglucopolysaccharides (Achromobacter spp., Agrobacterium radiobacter, Pseudomonas marginalis, Rhizobium spp. and Zooglea spp.) galactosaminogalactan (Aspergillus spp.) gellan (Aureomonas elodea and Sphingomonas paucimobilis) glucuronan (Sinorhizobium meliloti) N-acetylglucosamine (Staphylococcus epidermidis) N-acetyl-heparosan (Escherichia coli) hyaluronic acid (Streptococcus equi) indican (Beijerinckia indica) kefiran (Lactobacillus hilgardii) lentinan (Lentinus elodes) levan (Alcaligenes viscosus, Zymomonas mobilis, Bacillus subtilis) pullulan (Aureobasidium pullulans) scleroglucan (Sclerotium rolfsii, Sclerotium delfinii and Sclerotium glucanicum) schizophyllan (Schizophyllum commune) stewartan (Pantoea stewartii subsp. stewartii) succinoglycan (Alcaligenes faecalis var. myxogenes, Sinorhizobium meliloti) xanthan (Xanthomonas campestris) welan (Alcaligenes spp.)
== Release == To promote Half-Life, Valve's chief marketing officer, Monica Harrington, promoted Valve's reputation in the industry, with conference talks about their advances in game development, leading to coverage in the Wall Street Journal. Half-Life was released on November 19, 1998. When Sierra told Valve it was not planning to promote it beyond launch, Harrington threatened that Valve would "walk away from our agreement and tell the industry that had fallen in love with Valve how screwed up Sierra really was". In response, Sierra reissued Half-Life in a "Game of the Year" edition, boosting sales. In 2001, after renegotiating with Sierra, Valve gained the Half-Life intellectual property and online distribution rights for its games. Valve released two Half-Life demos. The first, Half-Life: Day One, contained the first fifth of the game and was distributed with certain graphic cards. The second, Half-Life: Uplink, was released on February 12, 1999, and featured original content. A short film based on Half-Life, also titled Half-Life: Uplink, was developed by Cruise Control, a British marketing agency, and released on February 11. The protagonist is a journalist who infiltrates the Black Mesa Research Facility, trying to discover what has happened there. Half-Life was censored in Germany to comply with the Federal Department for Media Harmful to Young Persons, which regulates depictions of violence against humans. Valve replaced the human characters with robots, spilling oil and gears instead of blood and body parts when killed, among other changes.
==== Blood-borne stimuli ==== Peptide hormones have important influences upon the hypothalamus, and to do so they must pass through the blood–brain barrier. The hypothalamus is bounded in part by specialized brain regions that lack an effective blood–brain barrier; the capillary endothelium at these sites is fenestrated to allow free passage of even large proteins and other molecules. Some of these sites are the sites of neurosecretion - the neurohypophysis and the median eminence. However, others are sites at which the brain samples the composition of the blood. Two of these sites, the SFO (subfornical organ) and the OVLT (organum vasculosum of the lamina terminalis) are so-called circumventricular organs, where neurons are in intimate contact with both blood and CSF. These structures are densely vascularized, and contain osmoreceptive and sodium-receptive neurons that control drinking, vasopressin release, sodium excretion, and sodium appetite. They also contain neurons with receptors for angiotensin, atrial natriuretic factor, endothelin and relaxin, each of which important in the regulation of fluid and electrolyte balance. Neurons in the OVLT and SFO project to the supraoptic nucleus and paraventricular nucleus, and also to preoptic hypothalamic areas. The circumventricular organs may also be the site of action of interleukins to elicit both fever and ACTH secretion, via effects on paraventricular neurons. It is not clear how all peptides that influence hypothalamic activity gain the necessary access.
Sources: en.wikipedia.org
As of this edit, this article uses content from "2.A.37 The Monovalent Cation:Proton Antiporter-2 (CPA2) Family", which is licensed in a way that permits reuse under the Creative Commons Attribution-ShareAlike 3.0 Unported License, but not under the GFDL. All relevant terms must be followed.
The Beauty is an American science fiction body horror television series created by Ryan Murphy and Matthew Hodgson. It is based on the comic book The Beauty, written by Jeremy Haun and Jason A. Hurley, and stars Evan Peters, Anthony Ramos, Jeremy Pope, Rebecca Hall, and Ashton Kutcher. The series premiered on FX and Hulu on January 21, 2026. In July 2026, it was reported that the entire cast had been released so the actors can pursue other projects, leaving the future of the series unclear.
=== Rats === African giant pouched rats were trained to diagnose more than 14000 tuberculosis patients by smelling sputum. Compared to dogs capable of sniffing around 10 samples of C. difficile in stool or E.coli in urine per day, rats could sniff up to 100 samples in 20 minutes. Their success rates of detection were comparable to smear examination by microscopy after Ziehl-Neelsen staining with a responsiveness of 94% (which are common tools to diagnose tuberculosis in low-income countries). Their sensitivity was lower in comparison to nucleic acid amplification tests (80%) and with culture (60–70%). The rats were regarded as a good diagnostic tool for tuberculosis despite their lower responsiveness than nucleic acid tests when diagnostic settings are highly endemic countries with peripheral medical centers without proper laboratory set-ups.
Sources: en.wikipedia.org
It is a synthetic peptide that activates both the GIP and GLP-1 receptors, making it a dual agonist. Approved products are given by injection rather than by mouth. It is not a small molecule and does not belong to the older sulfonylurea or thiazolidinedione families.
Engaging two receptors recruits signaling pathways that only partly coincide. This can shift the magnitude of effects on insulin release, glucagon levels and appetite relative to selective agents. Whether the pairing delivers benefits beyond a simple sum of the two is still debated in the literature.
The proportional contribution of each receptor to observed clinical effects has not been fully separated. Long-term consequences of continuous dual stimulation are likewise unclear. Investigators continue to probe these points through laboratory and clinical work.
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.